Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

A Pilot Study to Investigate the Balance between Proteases and α1-Antitrypsin in Bronchoalveolar Lavage Fluid of Lung Transplant Recipients.

Cagnone M, Piloni D, Ferrarotti I, Di Venere M, Viglio S, Magni S, Bardoni A, Salvini R, Fumagalli M, Iadarola P, Martinello S, Meloni F.

High Throughput. 2019 Feb 13;8(1). pii: E5. doi: 10.3390/ht8010005.

2.

Lymph-node mapping in lung cancer staging: accuracy and limits of the current approaches.

Piloni D, Stella GM.

Minerva Med. 2018 Dec;109(6 Suppl 1):6-10. doi: 10.23736/S0026-4806.18.05919-0.

3.

Asthma-like symptoms: is it always a pulmonary issue?

Piloni D, Tirelli C, Domenica RD, Conio V, Grosso A, Ronzoni V, Antonacci F, Totaro P, Corsico AG.

Multidiscip Respir Med. 2018 Aug 3;13:21. doi: 10.1186/s40248-018-0136-5. eCollection 2018.

4.

Effect of induction therapy on peripheral blood lymphocytes after lung transplantation: A multicenter international study.

Coiffard B, Piloni D, Boucekine M, Morosini M, Meloni F, Kessler R, Reynaud-Gaubert M.

Transpl Immunol. 2018 Jun;48:47-54. doi: 10.1016/j.trim.2018.02.013. Epub 2018 Feb 21. No abstract available.

PMID:
29475091
5.

Prolonged-release oxycodone-naloxone for pain management in advanced EGFR wild-type lung cancer patients.

Stella GM, Piloni D, Ciuffreda A, Spiaggi E, Marino E, Ilardi M, Cavalloro F.

Minerva Med. 2018 Aug;109(4):337-340. doi: 10.23736/S0026-4806.18.05287-4. Epub 2018 Feb 19. No abstract available.

PMID:
29458242
6.

Exploring adjuvant epidermal growth factor receptor inhibition in non-small cell lung cancer.

Stella GM, Piloni D.

Minerva Med. 2017 Jun;108(3 Suppl 1):6-12. doi: 10.23736/S0026-4806.17.05322-8. Review.

7.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

8.

Analysis of long term CD4+CD25highCD127- T-reg cells kinetics in peripheral blood of lung transplant recipients.

Piloni D, Morosini M, Magni S, Balderacchi A, Scudeller L, Cova E, Oggionni T, Stella G, Tinelli C, Antonacci F, D'Armini AM, Meloni F.

BMC Pulm Med. 2017 Jul 18;17(1):102. doi: 10.1186/s12890-017-0446-y.

9.

Bioengineered gold nanoparticles targeted to mesenchymal cells from patients with bronchiolitis obliterans syndrome does not rise the inflammatory response and can be safely inhaled by rodents.

Cova E, Inghilleri S, Pandolfi L, Morosini M, Magni S, Colombo M, Piloni D, Finetti C, Ceccarelli G, Benedetti L, Cusella MG, Agozzino M, Corsi F, Allevi R, Mrakic-Sposta S, Moretti S, De Gregori S, Prosperi D, Meloni F.

Nanotoxicology. 2017 May;11(4):534-545. doi: 10.1080/17435390.2017.1317862. Epub 2017 Apr 27.

PMID:
28415888
10.

1H NMR To Evaluate the Metabolome of Bronchoalveolar Lavage Fluid (BALf) in Bronchiolitis Obliterans Syndrome (BOS): Toward the Development of a New Approach for Biomarker Identification.

Ciaramelli C, Fumagalli M, Viglio S, Bardoni AM, Piloni D, Meloni F, Iadarola P, Airoldi C.

J Proteome Res. 2017 Apr 7;16(4):1669-1682. doi: 10.1021/acs.jproteome.6b01038. Epub 2017 Mar 14.

PMID:
28245130
11.

Lung tumors, COPD and immune response: is epigenetics the bottom line?

Balestro E, Baraldo S, Piloni D, Stella GM.

Minerva Med. 2016 Dec;107(6 Suppl 1):1-8. Review.

12.

An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe.

Ruttens D, Verleden SE, Bijnens EM, Winckelmans E, Gottlieb J, Warnecke G, Meloni F, Morosini M, Van Der Bij W, Verschuuren EA, Sommerwerck U, Weinreich G, Kamler M, Roman A, Gomez-Olles S, Berastegui C, Benden C, Holm AM, Iversen M, Schultz HH, Luijk B, Oudijk EJ, Kwakkel-van Erp JM, Jaksch P, Klepetko W, Kneidinger N, Neurohr C, Corris P, Fisher AJ, Lordan J, Meachery G, Piloni D, Vandermeulen E, Bellon H, Hoffmann B, Vienneau D, Hoek G, de Hoogh K, Nemery B, Verleden GM, Vos R, Nawrot TS, Vanaudenaerde BM.

Eur Respir J. 2017 Jan 18;49(1). pii: 1600484. doi: 10.1183/13993003.00484-2016. Print 2017 Jan.

13.

Clinical utility of CD4+ function assessment (ViraCor-IBT ImmuKnow test) in lung recipients.

Piloni D, Magni S, Oggionni T, Benazzo A, Stella G, Scudeller L, Morosini M, Cova E, Meloni F.

Transpl Immunol. 2016 Jul;37:35-39. doi: 10.1016/j.trim.2016.04.001. Epub 2016 Apr 16.

PMID:
27095000
14.

MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer.

Stella GM, Senetta R, Inghilleri S, Verdun di Cantogno L, Mantovani C, Piloni D, Scudeller L, Meloni F, Papotti M, Ricardi U, Cassoni P.

Neuro Oncol. 2016 Apr;18(4):598-9. doi: 10.1093/neuonc/nov325. Epub 2016 Feb 23. No abstract available.

15.

BAL neutrophilia in azithromycin-treated lung transplant recipients: Clinical significance.

Vandermeulen E, Verleden SE, Ruttens D, Moelants E, Mortier A, Somers J, Bellon H, Piloni D, Dupont LJ, Van Raemdonck DE, Proost P, Schols D, Vos R, Verleden GM, Vanaudenaerde BM.

Transpl Immunol. 2015 Sep;33(1):37-44. doi: 10.1016/j.trim.2015.07.001. Epub 2015 Jul 11.

PMID:
26168736
16.

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.

Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, Canta M, Piloni D, Cemmi F, Sangiolo D, Gammaitoni L, Soster M, Marchiò S, Pozzi E, Morbini P, Luisetti M, Aglietta M, Grignani G, Stella GM.

BMC Cancer. 2015 May 8;15:374. doi: 10.1186/s12885-015-1363-1.

17.

Interleukin-17 receptor polymorphism predisposes to primary graft dysfunction after lung transplantation.

Somers J, Ruttens D, Verleden SE, Vandermeulen E, Piloni D, Wauters E, Lambrechts D, Vos R, Verleden GM, Vanaudenaerde B, van Raemdonck DE.

J Heart Lung Transplant. 2015 Jul;34(7):941-9. doi: 10.1016/j.healun.2015.03.009. Epub 2015 Mar 26.

PMID:
25935436
18.

Antibody-engineered nanoparticles selectively inhibit mesenchymal cells isolated from patients with chronic lung allograft dysfunction.

Cova E, Colombo M, Inghilleri S, Morosini M, Miserere S, Peñaranda-Avila J, Santini B, Piloni D, Magni S, Gramatica F, Prosperi D, Meloni F.

Nanomedicine (Lond). 2015 Jan;10(1):9-23. doi: 10.2217/nnm.13.208. Epub 2014 Feb 21.

PMID:
24559038
19.

Assessment and management of pulmonary alveolar proteinosis in a reference center.

Campo I, Mariani F, Rodi G, Paracchini E, Tsana E, Piloni D, Nobili I, Kadija Z, Corsico A, Cerveri I, Chalk C, Trapnell BC, Braschi A, Tinelli C, Luisetti M.

Orphanet J Rare Dis. 2013 Mar 13;8:40. doi: 10.1186/1750-1172-8-40.

Supplemental Content

Loading ...
Support Center